DocMorris AG

ROSE

CH0042615283

Drug Retailers

Market Closed - Swiss Exchange Other stock markets 11:30:50 2024-05-15 am EDT			5-day change	1st Jan Change
72.85 ^CHF	+0.21%		-2.87%	-1.22%

Apr. 23	DOCMORRIS : Deutsche Bank remains its Buy rating	ZD
Apr. 19	DOCMORRIS : Hauck & Aufhauser gives a Buy rating	ZD

Zur Rose Group AG Provides Revenue Guidance for the Fiscal 2020

August 19, 2020 at 01:00 am EDT

Zur Rose Group AG provided revenue guidance for the fiscal 2020. For the period, the company expects significant growth in prescription drugs and confirms the medium-term revenue outlook of more than CHF 3 billion.

Latest news about DocMorris AG

DOCMORRIS : Deutsche Bank remains its Buy rating	Apr. 23	ZD
DOCMORRIS : Hauck & Aufhauser gives a Buy rating	Apr. 19	ZD
Global markets live: DocMorris, Microsoft, Oracle, Micron, Netflix...	Apr. 18
DOCMORRIS : Gets a Buy rating from Warburg Research	Apr. 18	ZD
DOCMORRIS : Receives a Buy rating from Berenberg	Apr. 18	ZD
DOCMORRIS : Gets a Buy rating from Baader Bank	Apr. 17	ZD
DOCMORRIS : Deutsche Bank gives a Buy rating	Apr. 17	ZD
DOCMORRIS : Warburg Research reiterates its Buy rating	Apr. 16	ZD
DOCMORRIS : UBS reaffirms its Sell rating	Apr. 16	ZD
DOCMORRIS : Gets a Buy rating from Jefferies	Apr. 16	ZD
Swiss online drug delivery firm DocMorris reports slight miss in Q1 sales	Apr. 16	RE
DOCMORRIS : Jefferies keeps its Buy rating	Apr. 12	ZD
DOCMORRIS : Hauck & Aufhauser raises its recommendation to Buy	Apr. 12	ZD
DOCMORRIS : Deutsche Bank reaffirms its Buy rating	Apr. 11	ZD
DOCMORRIS : Receives a Buy rating from Jefferies	Apr. 10	ZD
DOCMORRIS : Baader Bank reaffirms its Buy rating	Apr. 10	ZD
DOCMORRIS : Warburg Research keeps its Buy rating	Apr. 10	ZD
DOCMORRIS : UBS reaffirms its Sell rating	Apr. 02	ZD
DOCMORRIS : Baader Bank maintains a Buy rating	Mar. 26	ZD
DOCMORRIS : Deutsche Bank keeps its Buy rating	Mar. 22	ZD
DOCMORRIS : Buy rating from Warburg Research	Mar. 22	ZD
DOCMORRIS : Receives a Buy rating from Warburg Research	Mar. 21	ZD
DOCMORRIS : Baader Bank remains its Buy rating	Mar. 21	ZD
Transcript : DocMorris AG, 2023 Earnings Call, Mar 21, 2024	Mar. 21
DOCMORRIS : Receives a Sell rating from UBS	Mar. 21	ZD

Chart DocMorris AG

Duration

Period

More charts

Company Profile

Zur Rose Group AG is a Switzerland-based company engaged in the drug distribution sector. The Company focuses on the wholesale trade of medicines, as well as operation of a mail-order pharmacy. The Company's activities are divided into two business segments: Zur Rose and DocMorris. The Zur Rose division includes wholesale business and provides drugs to medical doctors, health insurance companies, hospitals and healthcare companies, among others. The DocMorris division manages the mail-order business for drug retail. The Company operates in Switzerland, Germany and the Netherlands through a number of subsidiaries, such as Zur Rose Suisse AG, Zur Rose Pharma GmbH, BlueCare AG, DocMorris NV, Eurapon Pharmahandel GmbH and Vitalsana BV.

Sector

Drug Retailers

Calendar

2024-05-28 - UBS Swiss Day

More about the company

Income Statement Evolution

More financial data

Ratings for DocMorris AG

Trading Rating

Investor Rating

ESG Refinitiv

B-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

72.7 CHF

Average target price

99.24 CHF

Spread / Average Target

+36.51%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Drug Retailers

	1st Jan change	Capi.
DOCMORRIS AG	-1.22%	1B
WALGREENS BOOTS ALLIANCE, INC.	-31.05%	15.83B
JD HEALTH INTERNATIONAL INC.	-22.89%	12.31B
ALIBABA HEALTH INFORMATION TECHNOLOGY LIMITED	-24.53%	6.59B
YIFENG PHARMACY CHAIN CO., LTD.	+12.51%	6.45B
MATSUKIYOCOCOKARA & CO.	-12.43%	5.94B
NAHDI MEDICAL COMPANY	-0.15%	4.66B
CORPORATIVO FRAGUA, S.A.B. DE C.V.	+62.00%	4.59B
CLICKS GROUP LIMITED	-5.94%	3.96B
DASHENLIN PHARMACEUTICAL GROUP CO., LTD.	-8.76%	3.55B

Other Drug Retailers

DocMorris AG

Equities

ROSE

CH0042615283

Drug Retailers

Zur Rose Group AG Provides Revenue Guidance for the Fiscal 2020

EPS Revisions